Tuberous Sclerosis Complex Proteins 1 and 2 Control Serum-Dependent Translation in a TOP-Dependent and -Independent Manner

REFERENCES

• Avdulov, S., S. Li, V. Michalek, D. Burrichter, M. Peterson, D. M. Perlman, J. C. Manivel, N. Sonenberg, D. Yee, P. B. Bitterman, and V. A. Polunovsky. 2004. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5:553–563.
   PubMed Web of Science ®Google Scholar
• Barth-Baus, D., C. A. Stratton, L. Parrott, H. Myerson, O. Meyuhas, D. J. Templeton, G. E. Landreth, and J. O. Hensold. 2002. S6 phosphorylation-independent pathways regulate translation of 5′-terminal oligopyrimidine tract-containing mRNAs in differentiating hematopoietic cells. Nucleic Acids Res. 30:1919–1928.
   PubMedGoogle Scholar
• Beretta, L., A. C. Gingras, Y. V. Svitkin, M. N. Hall, and N. Sonenberg. 1996. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 15:658–664.
   PubMed Web of Science ®Google Scholar
• Brugarolas, J., K. Lei, R. L. Hurley, B. D. Manning, J. H. Reiling, E. Hafen, L. A. Witters, L. W. Ellisen, and W. G. Kaelin, Jr. 2004. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18:2893–2904.
   PubMed Web of Science ®Google Scholar
• Brugarolas, J. B., F. Vazquez, A. Reddy, W. R. Sellers, and W. G. Kaelin, Jr. 2003. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147–158.
   PubMed Web of Science ®Google Scholar
• Byfield, M. P., J. T. Murray, and J. M. Backer. 2005. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280:33076–33082.
   PubMed Web of Science ®Google Scholar
• Caldarola, S., F. Amaldi, C. G. Proud, and F. Loreni. 2004. Translational regulation of terminal oligopyrimidine mRNAs induced by serum and amino acids involves distinct signaling events. J. Biol. Chem. 279:13522–13531.
   PubMedGoogle Scholar
• Cans, C., B. J. Passer, V. Shalak, V. Nancy-Portebois, V. Crible, N. Amzallag, D. Allanic, R. Tufino, M. Argentini, D. Moras, G. Fiucci, B. Goud, M. Mirande, R. Amson, and A. Telerman. 2003. Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc. Natl. Acad. Sci. USA 100:13892–13897.
   PubMed Web of Science ®Google Scholar
• Chiu, M. I., H. Katz, and V. Berlin. 1994. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. USA 91:12574–12578.
   PubMed Web of Science ®Google Scholar
• Chong-Kopera, H., K. Inoki, Y. Li, T. Zhu, F. R. Garcia-Gonzalo, J. L. Rosa, and K. L. Guan. 2006. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem. 281:8313–8316.
   PubMed Web of Science ®Google Scholar
• Corradetti, M. N., and K. L. Guan. 2006. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 25:6347–6360.
   PubMed Web of Science ®Google Scholar
• Dabora, S. L., S. Jozwiak, D. N. Franz, P. S. Roberts, A. Nieto, J. Chung, Y. S. Choy, M. P. Reeve, E. Thiele, J. C. Egelhoff, J. Kasprzyk-Obara, D. Domanska-Pakiela, and D. J. Kwiatkowski. 2001. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68:64–80.
   PubMed Web of Science ®Google Scholar
• Frias, M. A., C. C. Thoreen, J. D. Jaffe, W. Schroder, T. Sculley, S. A. Carr, and D. M. Sabatini. 2006. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 16:1865–1870.
   PubMed Web of Science ®Google Scholar
• Frodin, M., T. L. Antal, B. A. Dummler, C. J. Jensen, M. Deak, S. Gammeltoft, and R. M. Biondi. 2002. A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. EMBO J. 21:5396–5407.
   PubMedGoogle Scholar
• Gau, C. L., J. Kato-Stankiewicz, C. Jiang, S. Miyamoto, L. Guo, and F. Tamanoi. 2005. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Mol. Cancer Ther. 4:918–926.
   PubMedGoogle Scholar
• Gray, N. K., and M. Wickens. 1998. Control of translation initiation in animals. Annu. Rev. Cell Dev. Biol. 14:399–458.
   PubMed Web of Science ®Google Scholar
• Grolleau, A., J. Bowman, B. Pradet-Balade, E. Puravs, S. Hanash, J. A. Garcia-Sanz, and L. Beretta. 2002. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J. Biol. Chem. 277:22175–22184.
   PubMedGoogle Scholar
• Guertin, D. A., and D. M. Sabatini. 2005. An expanding role for mTOR in cancer. Trends Mol. Med. 11:353–361.
   PubMed Web of Science ®Google Scholar
• Hahn-Windgassen, A., V. Nogueira, C. C. Chen, J. E. Skeen, N. Sonenberg, and N. Hay. 2005. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 280:32081–32089.
   PubMed Web of Science ®Google Scholar
• Hara, K., Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, and K. Yonezawa. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177–189.
   PubMed Web of Science ®Google Scholar
• Harrington, L. S., G. M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rebholz, J. Barnett, N. R. Leslie, S. Cheng, P. R. Shepherd, I. Gout, C. P. Downes, and R. F. Lamb. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213–223.
   PubMed Web of Science ®Google Scholar
• He, L., and G. J. Hannon. 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5:522–531.
   PubMed Web of Science ®Google Scholar
• Herbert, T. P., G. R. Kilhams, I. H. Batty, and C. G. Proud. 2000. Distinct signalling pathways mediate insulin and phorbol ester-stimulated eukaryotic initiation factor 4F assembly and protein synthesis in HEK 293 cells. J. Biol. Chem. 275:11249–11256.
   PubMedGoogle Scholar
• Holz, M. K., B. A. Ballif, S. P. Gygi, and J. Blenis. 2005. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123:569–580.
   PubMed Web of Science ®Google Scholar
• Hornstein, E., H. Tang, and O. Meyuhas. 2001. Mitogenic and nutritional signals are transduced into translational efficiency of TOP mRNAs. Cold Spring Harbor Symp. Quant. Biol. 66:477–484.
   PubMedGoogle Scholar
• Inoki, K., Y. Li, T. Zhu, J. Wu, and K. L. Guan. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:648–657.
   PubMed Web of Science ®Google Scholar
• Inoki, K., T. Zhu, and K. L. Guan. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590.
   PubMed Web of Science ®Google Scholar
• Jacinto, E., V. Facchinetti, D. Liu, N. Soto, S. Wei, S. Y. Jung, Q. Huang, J. Qin, and B. Su. 2006. SIN1/MIP1 maintains Rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125–137.
   PubMed Web of Science ®Google Scholar
• Jacinto, E., R. Loewith, A. Schmidt, S. Lin, M. A. Ruegg, A. Hall, and M. N. Hall. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6:1122–1128.
   PubMed Web of Science ®Google Scholar
• Jaeschke, A., J. Hartkamp, M. Saitoh, W. Roworth, T. Nobukuni, A. Hodges, J. Sampson, G. Thomas, and R. Lamb. 2002. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol. 159:217–224.
   PubMedGoogle Scholar
• Jefferies, H. B., S. Fumagalli, P. B. Dennis, C. Reinhard, R. B. Pearson, and G. Thomas. 1997. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 16:3693–3704.
   PubMed Web of Science ®Google Scholar
• Jefferies, H. B., C. Reinhard, S. C. Kozma, and G. Thomas. 1994. Rapamycin selectively represses translation of the “polypyrimidine tract” mRNA family. Proc. Natl. Acad. Sci. USA 91:4441–4445.
   PubMed Web of Science ®Google Scholar
• Kaper, F., N. Dornhoefer, and A. J. Giaccia. 2006. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 66:1561–1569.
   PubMedGoogle Scholar
• Karbowniczek, M., T. Cash, M. Cheung, G. P. Robertson, A. Astrinidis, and E. P. Henske. 2004. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J. Biol. Chem. 279:29930–29937.
   PubMed Web of Science ®Google Scholar
• Kim, D. H., D. D. Sarbassov, S. M. Ali, R. R. Latek, K. V. Guntur, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2003. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11:895–904.
   PubMed Web of Science ®Google Scholar
• Koromilas, A. E., A. Lazaris-Karatzas, and N. Sonenberg. 1992. mRNAs containing extensive secondary structure in their 5′ non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J. 11:4153–4158.
   PubMed Web of Science ®Google Scholar
• Kovacina, K. S., G. Y. Park, S. S. Bae, A. W. Guzzetta, E. Schaefer, M. J. Birnbaum, and R. A. Roth. 2003. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem. 278:10189–10194.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski, D. J., H. Zhang, J. L. Bandura, K. M. Heiberger, M. Glogauer, N. el-Hashemite, and H. Onda. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11:525–534.
   PubMed Web of Science ®Google Scholar
• Larsson, O., D. M. Perlman, D. Fan, C. S. Reilly, M. Peterson, C. Dahlgren, Z. Liang, S. Li, V. A. Polunovsky, C. Wahlestedt, and P. B. Bitterman. 2006. Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an antiapoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res. 34:4375–4386.
   PubMed Web of Science ®Google Scholar
• Ledda, M., M. Di Croce, B. Bedini, F. Wannenes, M. Corvaro, P. P. Boyl, S. Caldarola, F. Loreni, and F. Amaldi. 2005. Effect of 3′UTR length on the translational regulation of 5′-terminal oligopyrimidine mRNAs. Gene 344:213–220.
   PubMedGoogle Scholar
• Ma, L., Z. Chen, H. Erdjument-Bromage, P. Tempst, and P. P. Pandolfi. 2005. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121:179–193.
   PubMed Web of Science ®Google Scholar
• Mamane, Y., E. Petroulakis, Y. Martineau, T. A. Sato, O. Larsson, V. K. Rajasekhar, and N. Sonenberg. 2007. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE 2:e242.
   PubMed Web of Science ®Google Scholar
• Mamane, Y., E. Petroulakis, L. Rong, K. Yoshida, L. W. Ler, and N. Sonenberg. 2004. eIF4E: from translation to transformation. Oncogene 23:3172–3179.
   PubMed Web of Science ®Google Scholar
• Manning, B. D., and L. C. Cantley. 2003. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans. 31:573–578.
   PubMed Web of Science ®Google Scholar
• Manning, B. D., A. R. Tee, M. N. Logsdon, J. Blenis, and L. C. Cantley. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10:151–162.
   PubMed Web of Science ®Google Scholar
• Mothe-Satney, I., D. Yang, P. Fadden, T. A. Haystead, and J. C. Lawrence, Jr. 2000. Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Mol. Cell. Biol. 20:3558–3567.
   PubMedGoogle Scholar
• Neshat, M. S., I. K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J. J. Gibbons, H. Wu, and C. L. Sawyers. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98:10314–10319.
   PubMed Web of Science ®Google Scholar
• Nielsen, F. C., L. Ostergaard, J. Nielsen, and J. Christiansen. 1995. Growth-dependent translation of IGF-II mRNA by a rapamycin-sensitive pathway. Nature 377:358–362.
   PubMedGoogle Scholar
• Nobukuni, T., M. Joaquin, M. Roccio, S. G. Dann, S. Y. Kim, P. Gulati, M. P. Byfield, J. M. Backer, F. Natt, J. L. Bos, F. J. Zwartkruis, and G. Thomas. 2005. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl. Acad. Sci. USA 102:14238–14243.
   PubMed Web of Science ®Google Scholar
• Pedersen, S., J. E. Celis, J. Nielsen, J. Christiansen, and F. C. Nielsen. 1997. Distinct repression of translation by wortmannin and rapamycin. Eur. J. Biochem. 247:449–456.
   PubMedGoogle Scholar
• Pende, M., S. H. Um, V. Mieulet, M. Sticker, V. L. Goss, J. Mestan, M. Mueller, S. Fumagalli, S. C. Kozma, and G. Thomas. 2004. S6K1(−/−)/S6K2(−/−) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24:3112–3124.
   PubMed Web of Science ®Google Scholar
• Pickering, B. M., and A. E. Willis. 2005. The implications of structured 5′ untranslated regions on translation and disease. Semin. Cell Dev. Biol. 16:39–47.
   PubMed Web of Science ®Google Scholar
• Podsypanina, K., R. T. Lee, C. Politis, I. Hennessy, A. Crane, J. Puc, M. Neshat, H. Wang, L. Yang, J. Gibbons, P. Frost, V. Dreisbach, J. Blenis, Z. Gaciong, P. Fisher, C. Sawyers, L. Hedrick-Ellenson, and R. Parsons. 2001. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc. Natl. Acad. Sci. USA 98:10320–10325.
   PubMed Web of Science ®Google Scholar
• Proud, C. G. 2002. Control of the translational machinery in mammalian cells. Eur. J. Biochem. 269:5337.
   PubMedGoogle Scholar
• Roux, P. P., D. Shahbazian, H. Vu, M. K. Holz, M. S. Cohen, J. Taunton, N. Sonenberg, and J. Blenis. 2007. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J. Biol. Chem. 282:14056–14064.
   PubMed Web of Science ®Google Scholar
• Ruvinsky, I., N. Sharon, T. Lerer, H. Cohen, M. Stolovich-Rain, T. Nir, Y. Dor, P. Zisman, and O. Meyuhas. 2005. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 19:2199–2211.
   PubMed Web of Science ®Google Scholar
• Sabatini, D. M. 2006. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6:729–734.
   PubMed Web of Science ®Google Scholar
• Sabatini, D. M., H. Erdjument-Bromage, M. Lui, P. Tempst, and S. H. Snyder. 1994. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35–43.
   PubMed Web of Science ®Google Scholar
• Saito, K., Y. Araki, K. Kontani, H. Nishina, and T. Katada. 2005. Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin. J. Biochem. 137:423–430.
   PubMedGoogle Scholar
• Sancak, Y., C. C. Thoreen, T. R. Peterson, R. A. Lindquist, S. A. Kang, E. Spooner, S. A. Carr, and D. M. Sabatini. 2007. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25:903–915.
   PubMed Web of Science ®Google Scholar
• Sarbassov, D. D., S. M. Ali, D. H. Kim, D. A. Guertin, R. R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14:1296–1302.
   PubMed Web of Science ®Google Scholar
• Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 307:1098–1101.
   PubMed Web of Science ®Google Scholar
• Schwab, M. S., S. H. Kim, N. Terada, C. Edfjall, S. C. Kozma, G. Thomas, and J. L. Maller. 1999. p70(S6K) controls selective mRNA translation during oocyte maturation and early embryogenesis in Xenopus laevis. Mol. Cell. Biol. 19:2485–2494.
   PubMedGoogle Scholar
• Shah, O. J., and T. Hunter. 2004. Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex. J. Biol. Chem. 279:20816–20823.
   PubMed Web of Science ®Google Scholar
• Shah, O. J., and T. Hunter. 2005. Tuberous sclerosis and insulin resistance: unlikely bedfellows reveal a TORrid affair. Cell Cycle 4:46–51.
   PubMed Web of Science ®Google Scholar
• Shaw, R. J., and L. C. Cantley. 2006. Ras, PI(3)K, and mTOR signalling controls tumour cell growth. Nature 441:424–430.
   PubMed Web of Science ®Google Scholar
• Shiota, C., J. T. Woo, J. Lindner, K. D. Shelton, and M. A. Magnuson. 2006. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11:583–589.
   PubMed Web of Science ®Google Scholar
• Smith, E. M., S. G. Finn, A. R. Tee, G. J. Browne, and C. G. Proud. 2005. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem. 280:18717–18727.
   PubMed Web of Science ®Google Scholar
• Stolovich, M., H. Tang, E. Hornstein, G. Levy, R. Cohen, S. S. Bae, M. J. Birnbaum, and O. Meyuhas. 2002. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell. Biol. 22:8101–8113.
   PubMedGoogle Scholar
• Tominaga, Y., T. Tamguney, M. Kolesnichenko, B. Bilanges, and D. Stokoe. 2005. Translational deregulation in PDK-1−/− embryonic stem cells. Mol. Cell. Biol. 25:8465–8475.
   PubMedGoogle Scholar
• Um, S. H., D. D'Alessio, and G. Thomas. 2006. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 3:393–402.
   PubMed Web of Science ®Google Scholar
• Vander Haar, E., S. I. Lee, S. Bandhakavi, T. J. Griffin, and D. H. Kim. 2007. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9:316–323.
   PubMed Web of Science ®Google Scholar
• Wang, L., and C. G. Proud. 2002. Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circ. Res. 91:821–829.
   PubMed Web of Science ®Google Scholar
• Wang, L., X. Wang, and C. G. Proud. 2000. Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps. Am. J. Physiol. Heart Circ. Physiol. 278:H1056–H1068.
   PubMed Web of Science ®Google Scholar
• Wang, X., W. Li, J. L. Parra, A. Beugnet, and C. G. Proud. 2003. The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol. Cell. Biol. 23:1546–1557.
   PubMed Web of Science ®Google Scholar
• West, M. J., M. Stoneley, and A. E. Willis. 1998. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene 17:769–780.
   PubMed Web of Science ®Google Scholar
• Wullschleger, S., R. Loewith, and M. N. Hall. 2006. TOR signaling in growth and metabolism. Cell 124:471–484.
   PubMed Web of Science ®Google Scholar
• Zhang, H., G. Cicchetti, H. Onda, H. B. Koon, K. Asrican, N. Bajraszewski, F. Vazquez, C. L. Carpenter, and D. J. Kwiatkowski. 2003. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Investig. 112:1223–1233.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., X. Gao, L. J. Saucedo, B. Ru, B. A. Edgar, and D. Pan. 2003. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5:578–581.
   PubMed Web of Science ®Google Scholar
• Zhu, J., E. D. Spencer, and R. L. Kaspar. 2003. Differential translation of TOP mRNAs in rapamycin-treated human B lymphocytes. Biochim. Biophys. Acta 1628:50–55.
   PubMedGoogle Scholar